目的 :观察吡嗪酰胺凝胶体外抗结核作用和支气管介入的安全性。方法 :手工法、仪器法分别测定吡嗪酰胺单体、吡嗪酰胺凝胶的最小抑菌浓度 (MIC)和最小杀菌浓度 (MBC)及家兔经支气管介入的安全性试验。结果 :吡嗪酰胺凝胶对人型结核分枝杆菌标准株、牛型结核分枝杆菌、草分枝杆菌MIC值分别为1mg/L、1mg/L、10mg/L ,MBC值分别为10mg/L、10mg/L、40mg/L ;吡嗪酰胺凝胶与吡嗪酰胺单体MIC、MBC值无显著性差异 ;动物安全性试验阴性。结论 :吡嗪酰胺凝胶具有与吡嗪酰胺单体相同的抗结核菌药效 ,卡波姆基质不影响吡嗪酰胺的抗菌活性 ;卡波姆基质吡嗪酰胺凝胶应用安全 OBJECTIVE: To observe the anti-TB effect of pyrazinamide gel in vitro and the safety of bronchial intervention. Methods: The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of pyrazinamide monomer and pyrazinamide gel and the safety tests of bronchial intervention in rabbits were respectively determined by manual method and instrumental method. Results: MIC value of pyrazinamide gel for standard strains of Mycobacterium tuberculosis, Mycobacterium bovis and Mycobacterium phlei were 1 mg / L, 1 mg / L and 10 mg / L respectively, MBC values ​​were 10 mg / L, 10mg / L, 40mg / L; pyrazinamide gel and pyrazinamide monomer MIC, MBC value no significant difference; animal safety test was negative. CONCLUSION: The pyrazinamide gel has the same anti-TB efficacy as the pyrazinamide monomer. The carbomer matrix does not affect the antimicrobial activity of the pyrazinamide. The carbomer amide pyrazinamide gel is safe